Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors

Gelijkaardige items

• Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment
  door: Horton, Brendan, et al.
  Gepubliceerd in: (2015)
• LAG-3 and 4-1BB identify dysfunctional antigen-specific T cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control
  door: Williams, Jason B, et al.
  Gepubliceerd in: (2015)
• Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
  door: Spranger, Stefani, et al.
  Gepubliceerd in: (2013)
• Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
  door: Spranger, Stefani, et al.
  Gepubliceerd in: (2014)
• The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8(+) T cells in the tumor microenvironment
  door: Williams, Jason B., et al.
  Gepubliceerd in: (2017)